Everolimus
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Fox Chase Cancer CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab National Cancer Institute (NCI) | Phase 1/2 | B |
Irinotecan AIDS Malignancy Consortium | Phase 1/2 | B |
Carboplatin Rapa Therapeutics LLC | Phase 1/2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Enzalutamide MacroGenics | Phase 2 | CCC |
View all 22 →
Same molecule, other indications
Everolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →